Generate Biomedicines, Inc. (GENB)

Generate Biomedicines will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

Generate Biomedicines Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	31.89	20.46
Revenue Growth (YoY)	55.89%	-
Gross Profit	31.89	20.46
Selling, General & Admin	42.26	42.09
Research & Development	224.7	175.31
Operating Expenses	266.96	217.4
Operating Income	-235.07	-196.94
Interest Expense (Income)	-12.53	-16
Other Expense (Income)	0.26	0.23
Pretax Income	-202.99	-173.56
Income Tax	0.16	0.21
Net Income	-222.97	-181.38
Net Income Common	-203.15	-173.77
Free Cash Flow	-204.13	-121.2
Gross Margin	100.00%	100.00%
Operating Margin	-737.04%	-962.60%
Profit Margin	-636.99%	-849.36%
Free Cash Flow Margin	-640.06%	-592.39%
EBITDA	-224.93	-187.27
EBITDA Margin	-705.27%	-915.35%
Depreciation & Amortization	10.4	9.9
EBIT	-235.33	-197.17
EBIT Margin	-737.86%	-963.74%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).